Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
|Videos|December 13, 2019
Outcomes in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Outcomes in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Advertisement
Case: 83-Year-Old Man With NDMM Ineligible for Transplant
History and Presentation:
- 83-year-old man c/o back pain and fatigue
- Cardiac stent placed 3 years ago; high blood pressure; BMI 32
Diagnostic Workup:
- Laboratory findings
- M-protein 3.8 g/dL
- Hb 7.9 g/dL
- LDH 290 IU/L
- Albumin 3.9 g/dL
- β2-microglobulin 4.25 mg/L
- Creatinine 1.5 mg/dL
- FLC kappa 134 mg/dL
- Bone marrow biopsy
- Good cellularity with 60% bone marrow plasma cells
- Cytogenetics/FISH: standard-risk, no cytogenetic abnormalities
- Imaging
- MRI of the spine: multiple focal lesions; moderate diffuse infiltration of spine, pelvis, and proximal femurs.
- ECOG PS: 2
- Durie-Salmon PLUS Stage IIIA IgG multiple myeloma requiring treatment with symptomatic anemia and bone lesions
Treatment:
Patient was started on D-Rd
Advertisement
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5